<!DOCTYPE html>
<html>
<head>
<meta name="Generator" content="Hancom HWP 10.30.11.3086">
<meta http-equiv="Content-Type" content="text/html; charset=euc-kr"><title></title>
<style type="text/css">
*{
	margin:0;
	padding:0;
}
.HStyle0 {
	style-name:"Normal";
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:160%;
	font-size:10.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle1 {
	style-name:"º»¹®";
	margin-left:15.0pt;
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:160%;
	font-size:10.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle2 {
	style-name:"°³¿ä 1";
	margin-left:10.0pt;
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:160%;
	font-size:10.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle3 {
	style-name:"°³¿ä 2";
	margin-left:20.0pt;
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:160%;
	font-size:10.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle4 {
	style-name:"°³¿ä 3";
	margin-left:30.0pt;
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:160%;
	font-size:10.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle5 {
	style-name:"°³¿ä 4";
	margin-left:40.0pt;
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:160%;
	font-size:10.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle6 {
	style-name:"°³¿ä 5";
	margin-left:50.0pt;
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:160%;
	font-size:10.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle7 {
	style-name:"°³¿ä 6";
	margin-left:60.0pt;
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:160%;
	font-size:10.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle8 {
	style-name:"°³¿ä 7";
	margin-left:70.0pt;
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:160%;
	font-size:10.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle9 {
	style-name:"°³¿ä 8";
	margin-left:80.0pt;
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:160%;
	font-size:10.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle10 {
	style-name:"°³¿ä 9";
	margin-left:90.0pt;
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:160%;
	font-size:10.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle11 {
	style-name:"°³¿ä 10";
	margin-left:100.0pt;
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:160%;
	font-size:10.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle12 {
	style-name:"ÂÊ ¹øÈ£";
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:160%;
	font-size:10.0pt;
	font-family:HCR Dotum;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle13 {
	style-name:"¸Ó¸®¸»";
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:0.0pt;
	line-height:150%;
	font-size:9.0pt;
	font-family:HCR Dotum;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle14 {
	style-name:"°¢ÁÖ";
	margin-left:13.1pt;
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:-13.1pt;
	line-height:130%;
	font-size:9.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle15 {
	style-name:"¹ÌÁÖ";
	margin-left:13.1pt;
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:justify;
	text-indent:-13.1pt;
	line-height:130%;
	font-size:9.0pt;
	font-family:HCR Batang;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle16 {
	style-name:"¸Þ¸ð";
	margin-top:0.0pt;
	margin-bottom:0.0pt;
	text-align:left;
	text-indent:0.0pt;
	line-height:130%;
	font-size:9.0pt;
	font-family:HCR Dotum;
	letter-spacing:-5%;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle17 {
	style-name:"Â÷·Ê Á¦¸ñ";
	margin-top:12.0pt;
	margin-bottom:3.0pt;
	text-align:left;
	text-indent:0.0pt;
	line-height:160%;
	font-size:16.0pt;
	font-family:HCR Dotum;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#2e74b5;
}
.HStyle18 {
	style-name:"Â÷·Ê 1";
	margin-top:0.0pt;
	margin-bottom:7.0pt;
	text-align:left;
	text-indent:0.0pt;
	line-height:160%;
	font-size:11.0pt;
	font-family:HCR Dotum;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle19 {
	style-name:"Â÷·Ê 2";
	margin-left:11.0pt;
	margin-top:0.0pt;
	margin-bottom:7.0pt;
	text-align:left;
	text-indent:0.0pt;
	line-height:160%;
	font-size:11.0pt;
	font-family:HCR Dotum;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
.HStyle20 {
	style-name:"Â÷·Ê 3";
	margin-left:22.0pt;
	margin-top:0.0pt;
	margin-bottom:7.0pt;
	text-align:left;
	text-indent:0.0pt;
	line-height:160%;
	font-size:11.0pt;
	font-family:HCR Dotum;
	letter-spacing:0;
	font-weight:normal;
	font-style:normal;
	color:#000000;
}
</style>
<script type="text/javascript">
		var adjustStyle = function(borderWidth) {
 		var value = borderWidth.match(/([\d\.]+)(%|px|cm|em|in|mm|pc|pt|)/) || [0, 0, ''];
 		var width = parseFloat(value[1]);
 		var unit = value[2];
 		if (unit == 'cm') {
 			if (width > 0.0 && width < 0.03) {
 				width = 0.03;
 			}
 		} else if (unit == 'in') {
 			if (width > 0.0 && width < 0.02) {
 				width = 0.02;
 			}
 		} else if (unit == 'mm') {
 			if (width > 0.0 && width < 0.3) {
 				width = 0.3;
 			}
 		} else if (unit == 'pc') {
 			if (width > 0.0 && width < 0.07) {
 				width = 0.07;
 			}
 		} else if (unit == 'px') {
 			if (width > 0.0 && width < 1.0) {
 				width = 1.0;
 			}
 		} else if (unit == 'pt') {
 			if (width > 0.0 && width < 0.8) {
 				width = 0.8;
 			}
 		} else if (unit == 'em') {
 			/* do not support */
 		} else if (unit == '%') {
 			/* do not support */
 		}
 		borderWidth = width + unit;
 		return borderWidth; 	};
 	(function() {
 		if (navigator.userAgent.match(/AppleWebKit/g) != null) {
 			for (var shIndex = 0; shIndex< document.styleSheets.length; shIndex++) {
 				var styleSheet = document.styleSheets[shIndex];
 				var rules = styleSheet.rules;
 				for (var rlIndex = 0; rlIndex < rules.length; rlIndex++) {
 					var rule = rules[rlIndex];
 					rule.style.borderLeftWidth=adjustStyle(rule.style.borderLeftWidth);
 					rule.style.borderRightWidth=adjustStyle(rule.style.borderRightWidth);
 					rule.style.borderTopWidth=adjustStyle(rule.style.borderTopWidth);
 					rule.style.borderBottomWidth=adjustStyle(rule.style.borderBottomWidth);
 				}
 			}
 		}
 	})();
 	window.onload = function(){
 		if (navigator.userAgent.match(/AppleWebKit/g) != null) {
 			var styledElms = document.querySelectorAll('*[style]');
 			for (var loop = 0; loop < styledElms.length; loop++) {
 				var elm = styledElms[loop];
 				elm.style.borderLeftWidth=adjustStyle(elm.style.borderLeftWidth);
 				elm.style.borderRightWidth=adjustStyle(elm.style.borderRightWidth);
 				elm.style.borderTopWidth=adjustStyle(elm.style.borderTopWidth);
 				elm.style.borderBottomWidth=adjustStyle(elm.style.borderBottomWidth);
 			}
 		}
 	};
</script>
</head>
<body>

<p class=HStyle0 style='line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";font-weight:bold;line-height:120%'>Main Scientific Publications &#8211; Prof. Choi</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>1.&nbsp;&nbsp;&nbsp;&nbsp; Comparison of the data of a next-generationsequencing panel from K-MASTER project with that of orthogonal methods fordetecting targetable genetic alterations. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Choi JY, Kim JW, LimAR, Lee Y, Chang WJ, Lee S, Sung JS, Chung H-J, Lee JW, Kang EJ, Kim JS, Lim T,Kim HS, Kim YJ, Ahn MS, Kim YS, Park JH, Lim S, Cho SS, Cho JH, Sin SW, ParkKH, Kim YH. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";font-style:italic;line-height:120%'>Cancer Res Treat.</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'> 2021 May. Online Ahead of print. </span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:60.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>&nbsp;</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>2.&nbsp;&nbsp;&nbsp;&nbsp; E-cigarette and cigarette use among cancersurvivors versus general population: a case-control study in Korea. Paek J, SonS, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ.</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";font-style:italic;line-height:120%'>J Cancer Surviv.</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'> 2021 Jun 16. Online Ahead of print.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>&nbsp;</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>3.&nbsp;&nbsp;&nbsp; 2020 Korean guidelines for the management of metastatic prostate cancer. KimI-H, Shin SJ, Kang BW, Kang J, Kim D, Kim M, Kim JY, Kim CK, Kim H-J, Maeng CH,Park K, Park I, Bae WK, Sohn BS, Lee M-Y, Lee JL, Lee J, Lim ST, Lim JH, ChangH, Jung JY, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Kim YS, Cho J, Joung JY, Park SH, Lee HJ. Korean JIntern Med. 2021 Feb 10</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:60.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>&nbsp;</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>4.&nbsp;&nbsp;&nbsp;&nbsp; Antitumor activity and safety of sirolimus forsolid tumors with PIK3CA mutations: A multicenter, open-label, prospectivesingle-arm study (KM 02-01, KCSG UN17-16). Byeon S, Kang MJ, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>,Kim YJ, Kim M, Yun J, Yi SY, Kim JY, Kim ST, Lee J. Transl Cancer Res2020;9(5):3222-3230. (co-first)</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:60.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>&nbsp;</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>5.&nbsp;&nbsp;&nbsp;&nbsp; Impact of subsequent chemotherapy on thesurvival of elderly patients with extensive stage small cell lung cancer. KangEJ, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Lee SR, Sung HJ, Kim JS. Korean J Intern Med. 2020Nov;35(6):1468-1476 (co-first)</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>&nbsp;</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>6.&nbsp;&nbsp;&nbsp; A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependentosteoclastogenesis and breast cancer growth in the metastatic bonemicroenvironment. Kang J, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Seo BY, Jo U, Park SI, Kim YH, ParkKH. Sci Rep. 2019 Jun 19;9(1):8726. </span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:60.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>&nbsp;</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>7.&nbsp;&nbsp;&nbsp;&nbsp; Association between hand grip strength andimpaired health-related quality of life in Korean cancer survivors: across-sectional study. Paek J, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>. BMJ Open. 2019 Sep8;9(9):e030938.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:60.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>&nbsp;</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>8.&nbsp;&nbsp;&nbsp;&nbsp; Phase II Study of Dovitinib in Patients withCastration-Resistant Prostate Cancer (KCSG-GU11-05). </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Kim HS,Park SH, Kim B-S, Kim KH, Lee HJ, Song HS, Shin D-Y, Lee HY, Kim H-G, Lee KH,Lee JL, Park KH. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";font-style:italic;line-height:120%'>Cancer Res Treat.</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>2018 Ict;50(4):1252-1259.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>&nbsp;</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>9.&nbsp;&nbsp;&nbsp;&nbsp; A case report of primary pericardial malignantmesothelioma treated with pemetrexed and cisplatin. Kim JS, Lim SY, Hwang J,Kang EJ, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>. J Korean Med Sci. 2017;32:1879-1884.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:60.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>&nbsp;</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>10.The prognostic role of serum C-X-C chemokinereceptor type 4 in patients with metastatic or recurrent colorectal cancer. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>ChoiYJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Chang WJ, Shin SW, Park KH, Kim ST, Kim YJ. Oncotargets and Therapy.2016;9:3307-3312.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>&nbsp;</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>11.Randomized phase II study ofpaclitaxel/carboplatin intercalated with gefitinib compared topaclitaxel/carboplatin alone for chemotherapy-na&#239;ve non-small cell lung cancerin a clinically selected population excluding patients with non-smokingadenocarcinoma or mutated EGFR. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Lee DH, Choi CM, Lee JS, LeeSJ, Ahn J-H, Kim S-W. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";font-style:italic;line-height:120%'>BMC Cancer.</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>2015;15:763.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:60.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>&nbsp;</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>12.Phase II study of pemetrexed in combinationwith cisplatin in patients with advanced urothelial cancer: the PECULIAR study.</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Lee SH, Ahn J-H, Lee K-H, You D, Hong B, Hong JH, Ahn H. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";font-style:italic;line-height:120%'>Br J Cancer.</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'> 2015;112:260-265.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:60.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>&nbsp;</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>13.Pretreatment serum level of 15-kDa granulysinmight have a prognostic value in patients with diffuse large B cell lymphoma.Park Y, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Park SJ, Lee SR, Sung HJ, Park KH, Kim SJ, Choi CW,Jung KY, Kim BS. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";font-style:italic;line-height:120%'>Acta Haematol. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>2011;126(2):79-86.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>14.Epidermal growth factor receptor mutations as aprognostic factor in Korean patients with advanced lung adenocarcinoma who hadnot been treated with received epidermal growth factor receptor tyrosine kinaseinhibitors. Kim ST, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Park KH, Oh SC, Seo JH, Shin SW, Kim JS,Kim YH. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";font-style:italic;line-height:120%'>Chemotherapy. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>2011;57(2):108-14</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>15.A prognostic model to identify patients withadvanced pancreas adenocarcinoma who could benefit from second-linechemotherapy. Kim ST, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Park KH, Oh SC, Seo JH, Shin SW, Kim JS,Kim YH. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";font-style:italic;line-height:120%'>Clin Oncol (R Coll Radiol).</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>2012 Mar;24(2):105-11.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>16.Mitomycin-C, 5-fluorouracil, and leucovorin asa salvage therapy in patients with metastatic colorectal adenocarcinoma. KangEJ, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Kim JS, Kim ST, Park KH, Choi IK, Oh SC, Seo JH, Shin SW,Kim JS, Kim YH. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";font-style:italic;line-height:120%'>Asia Pac J Clin Oncol. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>2010Dec;6(4):286-91.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>17.Phase II study of dovitinib in patients withmetastatic and/or unresectable gastrointestinal stromal tumours after failureof imatinib and sunintinib. Y-K Kang, C Yoo, B-Y Ryoo, J J Lee, E Tan, I Park,J H Park, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Y J Choi</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, J Jo, J-S Ryu and M-H Ryu. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";font-style:italic;line-height:120%'>Br J Cancer</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>. 2013 Oct 29; 109(9):2309-15.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>18.Predictors of mortality attricutable toClostridium difficile infection in patients with underlying malignancy. YoonYK, Kim MJ, Sohn JW, Kim HS, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Kim JS, Kim ST, Park KH, Kim SJ,Kim BS, Shin SW, Kim YH, Park Y. Supportive Care Cancer. 2014;22:2039-2048.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>19.Prognostic factors for the selection ofpatients eligible for second-line chemotherapy in advanced biliary tractcancer. Kang EJ, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Kim JS, Park KH, Oh SC, Seo JH, Kim HJ, KangKW, Yu ES, Shin SW, Kim YH, Kim JS. Chemotherapy. 2014;60:91-98.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>20.Effectiveness and safety of cabazitaxel plusprednisolone chemotherapy for metastatic castration-resistant prostaticcarcinoma: data on Korean patients obtained by the cabazitaxelcompassionate-use program. Lee J-L, Park SH, Koh S-J, Kim YJ, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>,Lee J, Lim HY. Cancer Chemother Parmacol. 2014;74:1005-1013.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>21.Bladder and liver involvement of visceral larvamigrans may mimic malignancy. Kang EJ, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Kim JS, Lee BH, KangK-W, Kim HJ, Yu ES, Kim YH. Cancer Res Treat. 2014;46(4):419-424.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>22.Novel germline mutation of BRCA1 gene in a56-year-old woman with breast cancer, ovarian cancer, and diffuse large B-celllymphoma. Kim HS, Lee SW, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Shin SW, Kim YH, Cho MS, Lee SN, ParkKH. Cancer Res Treat. 2015 Jul;47(3):534-8.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>23.A Prognostic index to identify patients withintrahepatic cholangiocarcinoma who could benefit from gemcitabine pluscisplatin. Lee S-Y, Kim HS, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Park KH, Shin SW, Kim YH, Kim ST.Am J Ther. 2015 Jan 29. (Epub)</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>24.Can serum be used for analyzing the KRASmutation status in patients with advanced colorectal cancer? Kim ST, Shang WJ,Kin L, Sung JS, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Kim YH. Cancer Res Treat. 2015;47(4):796-803.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>25.The role of theaddition of ovarian suppression to tamoxifen in young women withhormone-sensitive breast cancer who remain premenopausal or regain menstruationafter chemotherapy (ASTRRA): study protocol for a randomized controlled trialand progress.KimHA, Ahn SH, Nam SJ, Park S, Ro J, Im SA, Jung YS, Yoon JH, Hur MH, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>,Lee SJ, Jeong J, Cho SH, Kim SY, Lee MH, Kim LS, Moon BI, Kim TH, Park C, KimSJ, Jung SH, Park H, Gwak GH, Kang SH, Kim JG, Kim J, Choi SY, Lim CW, Kim D,Yoo Y, Song YJ, Kang YJ, Jung SS, Shin HJ, Lee KJ, Han SH, Lee ES, Han W, KimHJ, Noh WC. BMC Cancer. 2016;16:319.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>26.Prognostic value of axillary nodal ratio afterneoadjuvant chemotherapy of doxorubicin/cyclophosphamide followed by docetaxel:a multicenter retrospective cohort study. Kim SH, Jung KH, Kim T-Y, Im S-A,Choi IS, Chae YS, Baek SK, Kang SY, Park S, Park IH, Lee KS, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>,Lee S, Sohn JH, Park Y-H, Im Y-H, Ahn J-H, Kim S-B, Kim JH. Cancer Research andTreatment. 2016;48(4):1373-1381.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>27.Incidence and predictors of febrile neutropeniaamong early-stage breast cancer patients receiving anthracycline-basedchemotherapy in Korea. Kim HS, Lee SY, Kim JW, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Park IH, Lee KS,Seo JH, Shin SW, Kim YH, Kim JS, Park KH. Oncology. 2016;91(5)274-282.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>28.Combination chemotherapy with methotrexate andvinblastine for surgically unresectable, aggressive fibromatosis. Park KH, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>ChoiYJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Kim KW, Ro KH, Kang CH, Song SH, Park JH. Jpn J Clin Oncol.2016;46(9):845-9.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>29.Overexpression of PD-L2 is associated withshorter relapse-free survival in patients with malignant salivary gland tumors.Chang H, Kim JS, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Cho JG, Woo JS, Kim A, Kim JS, Kang EJ. OncoTargets Ther. 2017;10:2983-2992.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>30.Feasibility andEfficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer:Korean Multi-center Phase IV Clinical Study Results. Park YH, Kim TY, Im YH,Lee KS, Park IH, Sohn J, Lee SH, Im SA, Kim JH, Kim SH, Lee SJ, Koh SJ, Lee KH,</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ,</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'> Cho EK, Lee S, Kang SY, Seo JH, Kim SB, Jung KH. Cancer ResTreat. 2017;49(2):423-429.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>31.Inflammatory markersas prognostic indicators in pancreatic cancer patients who underwentgemcitabine-based palliative chemotherapy. Kim HJ, Lee SY, Kim DS, Kang EJ, KimJS, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Oh SC, Seo JH, Kim JS. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";font-style:italic;line-height:120%'>KoreanJ Intern Med</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>. 2018 Oct 26.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>32.Incidence and riskfactors for congestive heart failure in patients with early breast cancer whoreceived anthracycline and/or trastuzumab: a big data analysis of the KoreanHealth Insurance Review and Assessment service database. Choi JY, Cho EY, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>ChoiYJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Lee JH, Jung SP, Cho KR, Kim CY, Kim YH, Park KH. Breast Cancer ResTreat. 2018 Aug;171(1):181-188.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>33.Detection of somaticvariants and EGFR mutations in cell-free DNA from non-small cell lung cancerpatients by ultra-deep sequencing using the ion ampliseq cancer hotspot paneland droplet digital polymerase chain reaction. Sung JS, Chong HY, Kwon NJ, KimHM, Lee JW, Kim B, Lee SB, Park CW, Choi JY, Chang WJ, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Lee SY,Kang EJ, Park KH, Kim YH. </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";font-style:italic;line-height:120%'>Oncotarget.</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>2017 Nov 15;8(63):106901-106912.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>34.Quantification ofcirculating cell-free DNA to predict patient survival in non-small-cell lungcancer. Hyun MH, Sung JS, Kang EJ, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Park KH, Shin SW, Lee SY,Kim YH. Oncotarget. 2017 Oct 10;8(55):94417-94430.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>35.Early venousthromboembolism at the beginning of palliative chemotherapy is a poorprognostic factor in patients with metastatic pancreatic cancer: aretrospective study. Kim JS, Kang EJ, Kim DS, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>ChoiYJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Lee SY, Kim HJ, SeoHY, Kim JS. BMC Cancer. 2018 Dec 17;18(1):1260.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>36.A Selective FGFRinhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent osteoclastogenesis andbreast cancer growth in the metastatic bone microenvironment. Kang J, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Seo BY, Jo U, Park SI, Kim YH, Park KH. Sci Rep.2019 Jun 19;9(1):8726.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>37.Clinical implicationsof circulating cell-free DNA quantification and metabolic tumor burden inadvanced non-small cell lung cancer. Hyun MH, Lee ES, Eo JS, Kim S, Kang EJ,Sung JS, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Park KH, Shin SW, Lee SY, Kim YH. Lung Cancr. 2019Aug;134:158-166.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>38.Completion rate ofphysician orders for life-sustaining treatment for patients with metastatic orrecurrent cancer: a preliminary, cross-sectional study. Kim JW, Choi JY, JangWJ, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Choi YS, Shin SW, Kim YH, Park KH. BMC PalliatCare. 2019 Oct 22;18(1):84.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>39.Gemcitabine pluscarboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patientswith advanced urothelial carcinoma: a randomized phase II study (COACH, KCSGGU10-16). Park I, Kim BS, Lim HY, Kim HJ, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>ChoiYJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Park KH, Lee KH,Yoon S, Hong B, Hong JH, Ahn H, Lee JL. Eur J Cancer. 2019Oct24.pii:S0959-8049(19)30727-0.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>40.Pulmonary function isimplicated in the prognosis of metastatic non-small cell lung cancer but not inextended disease small cell lung cancer. Lee SY, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>ChoiYJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Seo JH, Lee SY, KimJS, Kang EJ. J Thorac Dis. 2019 Nov;11(11):4562-4572.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>41.Innovativecountermeasures can maintain cancer care continuity during the coronavirusdisease-2019 pandemic in Korea. Lee S, Lim A-R, Kim MJ, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Kim JW,Park KH, Shin SW, Kim YH. Eur J Cancer. 2020 Sep;136:69-75.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>42.Pembrolizumab-Induced Myasthenic Crisis withHyperCKemia in a Patient with Thymoma. Shin JH, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Lee J, Baek SH. J Clin Neurol. 2020Jul;16(3):497-498.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>43.Clinical Implication of Concordant or DiscordantGenomic Profiling between Primary and Matched Metastatic Tissues in Patientswith Colorectal Cancer. Choi JY, Choi S, Lee M, Park YS, Sung JS, Chang WJ, KimJW, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Kim J, KimD-S, Lee S-H, Seok J, Park KH, Kim SH, Kim YH. Cancer Res Treat. 2020 Jul;52(3):764-778.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>44.The Clinical Significance of RAS, PIK3CA, andPTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA. Chang WJ,Sung JS, Lee SY, Kang EJ, Kwon N-J, Kim HM, Shin SW, Choi JY, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Kim JW, Park KH, Kim YH. Clin Med. 2020 Aug 14;9(8):2642.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

<p class=HStyle0 style='margin-left:20.0pt;text-indent:-20.0pt;line-height:120%;'><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>45.Clinical Application of Targeted DeepSequencing in Metastatic Colorectal Cancer Patients: Actionable GenomicAlteration in K-MASTER Project. Lee Y, Lee S, Sung JS, Chung H-J, Lim A-R, KimJW, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Park KH, KimYH. Cancer Res Treat. 2021 Jan;53(1):123-130.Treatment Patterns andClinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: ARetrospective Cohort Study. Bang S-M, Kang J-H, Hong MH, Ahn J-S, Oh SY, BaekJH, </span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";text-decoration:underline;line-height:120%'>Choi YJ</span><span style='position:relative;font-size:14.0pt;font-family:"Times New Roman,ÇÑÄÄµ¸¿ò";line-height:120%'>, Shin SH, Kim Y-J, Gil H-Y, Park H-E, Lee J, Park E-L. ClinAppl Thromb Hemost. Jan-Dec 2021;27:1076029620979575.</span><span class="hnc_page_break" style="display:relative;word-spacing:-0.5em;">&nbsp;</span></p>

</body>

</html>
